276 related articles for article (PubMed ID: 2147036)
1. SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes.
Nokin P; Clinet M; Beaufort P; Meysmans L; Laruel R; Chatelain P
J Pharmacol Exp Ther; 1990 Nov; 255(2):600-7. PubMed ID: 2147036
[TBL] [Abstract][Full Text] [Related]
2. High-affinity binding of DTZ323, a novel derivative of diltiazem, to rabbit skeletal muscle L-type Ca++ channels.
Hagiwara M; Adachi-Akahane S; Nagao T
J Pharmacol Exp Ther; 1997 Apr; 281(1):173-9. PubMed ID: 9103495
[TBL] [Abstract][Full Text] [Related]
3. Potential-dependent allosteric modulation of 1,4-dihydropyridine binding by d-(cis)-diltiazem and (+/-)-verapamil in living cardiac cells.
Porzig H; Becker C
Mol Pharmacol; 1988 Aug; 34(2):172-9. PubMed ID: 2457793
[TBL] [Abstract][Full Text] [Related]
4. Interaction of SR 33557 with skeletal muscle calcium channel blocker receptors in the baboon: characterization of its binding sites.
Sol-Rolland J; Joseph M; Rinaldi-Carmona M
J Pharmacol Exp Ther; 1991 May; 257(2):595-602. PubMed ID: 1851830
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the slow calcium channel binding sites for [3H]SR 33557 in rat heart sarcolemmal membranes.
Chatelain P; Beaufort P; Meysmans L; Clinet M
Mol Pharmacol; 1991 Jan; 39(1):64-71. PubMed ID: 1846221
[TBL] [Abstract][Full Text] [Related]
6. Selective modulation by membrane potential of desmethoxyverapamil binding to calcium channels in rat portal vein.
Rakotoarisoa L; Sayet I; Mironneau C; Mironneau J
J Pharmacol Exp Ther; 1990 Dec; 255(3):942-7. PubMed ID: 2175807
[TBL] [Abstract][Full Text] [Related]
7. Effects of cyproheptadine on [3H]-d-cis-diltiazem binding sites in cardiac sarcolemmal membranes of rats.
Xin HB; Zhang BH; Liu YW
Yao Xue Xue Bao; 1994; 29(9):641-6. PubMed ID: 7900533
[TBL] [Abstract][Full Text] [Related]
8. The relationship between the binding site of [3H]-d-cis-diltiazem and that of other non-dihydropyridine calcium entry blockers in cardiac sarcolemma.
Balwierczak JL; Johnson CL; Schwartz A
Mol Pharmacol; 1987 Feb; 31(2):175-9. PubMed ID: 2433570
[TBL] [Abstract][Full Text] [Related]
9. A novel high affinity class of Ca2+ channel blockers.
Qar J; Barhanin J; Romey G; Henning R; Lerch U; Oekonomopulos R; Urbach H; Lazdunski M
Mol Pharmacol; 1988 Apr; 33(4):363-9. PubMed ID: 2965787
[TBL] [Abstract][Full Text] [Related]
10. SR 33557, a novel calcium-antagonist: interaction with [3H]-(+/-)-nitrendipine and [3H]-(-)-desmethoxy-verapamil binding sites in cerebral membranes.
Nokin P; Clinet M; Polster P; Beaufort P; Meysmans L; Gougat J; Chatelain P
Naunyn Schmiedebergs Arch Pharmacol; 1989; 339(1-2):31-6. PubMed ID: 2542806
[TBL] [Abstract][Full Text] [Related]
11. Effects of Ca++ on [3H]diltiazem binding and its allosteric interaction with dihydropyridine calcium channel binding sites in the rat cortex.
Schoemaker H; Langer SZ
J Pharmacol Exp Ther; 1989 Feb; 248(2):710-5. PubMed ID: 2537412
[TBL] [Abstract][Full Text] [Related]
12. In vitro characterization of a novel Ca2+ entry blocker: SR 33805.
Chatelain P; Clinet M; Polster P; Christophe B; Manning AS
Eur J Pharmacol; 1993 Aug; 246(3):181-93. PubMed ID: 8223943
[TBL] [Abstract][Full Text] [Related]
13. SR33557, an indolizinsulfone blocker of Ca2+ channels: identification of receptor sites and analysis of its mode of action.
Schmid A; Romey G; Barhanin J; Lazdunski M
Mol Pharmacol; 1989 Jun; 35(6):766-73. PubMed ID: 2543910
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel nondihydropyridine Ca2+ channel activator, in cardiac and vascular preparations.
Zheng W; Rampe D; Triggle DJ
Mol Pharmacol; 1991 Nov; 40(5):734-41. PubMed ID: 1719369
[TBL] [Abstract][Full Text] [Related]
15. SR 33557, a novel calcium entry blocker. I. In vitro isolated tissue studies.
Polster P; Christophe B; Van Damme M; Houlliche A; Chatelain P
J Pharmacol Exp Ther; 1990 Nov; 255(2):593-9. PubMed ID: 1700816
[TBL] [Abstract][Full Text] [Related]
16. (-)-[3H] desmethoxyverapamil labels multiple calcium channel modulator receptors in brain and skeletal muscle membranes: differentiation by temperature and dihydropyridines.
Reynolds IJ; Snowman AM; Snyder SH
J Pharmacol Exp Ther; 1986 Jun; 237(3):731-8. PubMed ID: 3012067
[TBL] [Abstract][Full Text] [Related]
17. Calcium ions inhibit the allosteric interaction between the dihydropyridine and phenylalkylamine binding site on the voltage-gated calcium channel in heart sarcolemma but not in skeletal muscle transverse tubules.
Murphy BJ; Tuana BS
Can J Physiol Pharmacol; 1990 Nov; 68(11):1389-95. PubMed ID: 1962734
[TBL] [Abstract][Full Text] [Related]
18. Positive heterotropic allosteric regulators of dihydropyridine binding increase the Ca2+ affinity of the L-type Ca2+ channel. Stereoselective reversal by the novel Ca2+ antagonist BM 20.1140.
Staudinger R; Knaus HG; Glossmann H
J Biol Chem; 1991 Jun; 266(17):10787-95. PubMed ID: 1645709
[TBL] [Abstract][Full Text] [Related]
19. [3H]TA-3090, a selective benzothiazepine-type calcium channel receptor antagonist: in vitro characterization.
Zobrist RH; Mecca TE
J Pharmacol Exp Ther; 1990 May; 253(2):461-5. PubMed ID: 2338642
[TBL] [Abstract][Full Text] [Related]
20. A new class of calcium entry blockers defined by 1,3-diphosphonates. Interactions of SR-7037 (belfosdil) with receptors for calcium channel ligands.
Rossier JR; Cox JA; Niesor EJ; Bentzen CL
J Biol Chem; 1989 Oct; 264(28):16598-607. PubMed ID: 2550449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
